CoChat

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Open access
Hodges, Michael R., Ople, Eric, Wedel, Pamela, Shaw, Karen J., Jakate, Abhijeet, Kramer, William G., Marle, Sjoerd van, van Hoogdalem, Ewoud-Jan, Tawadrous, Margaret · 2023 · Antimicrobial Agents and Chemotherapy

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX, interferes with cell wall synthesis by targeting fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, thereby causing loss of cell viability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.01623-22

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 MGX concentration profile after single and multiple ascending i.v.-infused FMGX doses. (A) SAD cohorts; (B) MAD cohorts. (A and B) Data are presented for study 1 cohorts 1 to 6 and 11a (A) and cohorts 7 to 10 (B) as geometric mean MGX plasma concentrations for participants in the PK population (n = 5 for 50 mg, n = 6 for all other treatment groups) using linear (panel A, main figure and panel B) and semilogarithmic (panel A, inset) scales. All doses were infused over 3 h; doses were administered daily for the MAD segment. For panel A, the elimination half-life for the 10-mg dose was excluded from overall data interpretation because it was biased by the sampling schedule at that first dose level. FMGX, fosmanogepix; IV, intravenous; MAD, multiple ascending dose; MGX, manogepix; n, number of participants; PK, pharmacokinetics; SAD, single ascending dose.
FIG 1 MGX concentration profile after single and multiple ascending i.v.-infused FMGX doses. (A) SAD cohorts; (B) MAD cohorts. (A and B) Data are presented for study 1 cohorts 1 to 6 and 11a (A) and cohorts 7 to 10 (B) as geometric mean MGX plasma concentrations for participants in the PK population (n = 5 for 50 mg, n = 6 for all other treatment groups) using linear (panel A, main figure and panel B) and semilogarithmic (panel A, inset) scales. All doses were infused over 3 h; doses were administered daily for the MAD segment. For panel A, the elimination half-life for the 10-mg dose was excluded from overall data interpretation because it was biased by the sampling schedule at that first dose level. FMGX, fosmanogepix; IV, intravenous; MAD, multiple ascending dose; MGX, manogepix; n, number of participants; PK, pharmacokinetics; SAD, single ascending dose.CC BY · PubMed Central
FIG 2 (A and B) Relationship of (A) Cmax and (B) AUC(∞) of MGX with dose after i.v. infusion of FMGX (SAD cohorts). Data are presented for study 1 cohorts 1 to 6 and 11a for Cmax (A) and AUC(∞) (B) of MGX for participants in the PK population. All doses were infused over 3 h (A) or 10 to 350 mg for 3 h and 1,000 mg over 0.5 to 3 h. AUC(∞), area under the concentration-time curve from time zero to infinity; Cmax, maximum plasma concentration; FMGX, fosmanogepix; IV, intravenous; MGX, manogepix; n, number of participants; PK, pharmacokinetics.
FIG 2 (A and B) Relationship of (A) Cmax and (B) AUC(∞) of MGX with dose after i.v. infusion of FMGX (SAD cohorts). Data are presented for study 1 cohorts 1 to 6 and 11a for Cmax (A) and AUC(∞) (B) of MGX for participants in the PK population. All doses were infused over 3 h (A) or 10 to 350 mg for 3 h and 1,000 mg over 0.5 to 3 h. AUC(∞), area under the concentration-time curve from time zero to infinity; Cmax, maximum plasma concentration; FMGX, fosmanogepix; IV, intravenous; MGX, manogepix; n, number of participants; PK, pharmacokinetics.CC BY · PubMed Central
FIG 3 (A and B) Relationship of (A) Cmax and (B) AUC(0–24) of MGX with dose after i.v.-infused FMGX (MAD cohort). Data are presented for study 1 cohorts 7 and 8 for Cmax (A) and AUC(0–24) (B) of MGX for participants in the PK population. All doses were infused over 3 h QD × 14 days (A) or over 3 h QD × 14 days and on day 7 after i.v. infusion of 600 mg QD × 6 days preceded by 1,000 mg/1 h × 2 on day 1 (B). AUC0–24, area under the concentration-time curve from time 0 to 24 h postdose; Cmax, maximum plasma concentration; FMGX, fosmanogepix; IV, intravenous; MAD, multiple ascending dose; MGX, manogepix; n, number of participants; PK, pharmacokinetics; PO, oral; QD, once daily.
FIG 3 (A and B) Relationship of (A) Cmax and (B) AUC(0–24) of MGX with dose after i.v.-infused FMGX (MAD cohort). Data are presented for study 1 cohorts 7 and 8 for Cmax (A) and AUC(0–24) (B) of MGX for participants in the PK population. All doses were infused over 3 h QD × 14 days (A) or over 3 h QD × 14 days and on day 7 after i.v. infusion of 600 mg QD × 6 days preceded by 1,000 mg/1 h × 2 on day 1 (B). AUC0–24, area under the concentration-time curve from time 0 to 24 h postdose; Cmax, maximum plasma concentration; FMGX, fosmanogepix; IV, intravenous; MAD, multiple ascending dose; MGX, manogepix; n, number of participants; PK, pharmacokinetics; PO, oral; QD, once daily.CC BY · PubMed Central
FIG 4 MGX single-dose concentration profile over shortened i.v. infusion times. Data are presented for study 1 cohorts 11a to 11d as geometric mean MGX plasma concentrations for participants in the PK population (n = 6 per group) using linear (main figure) and semilogarithmic (inset) scales. IV, intravenous; n, number of participants; MGX, manogepix.
FIG 4 MGX single-dose concentration profile over shortened i.v. infusion times. Data are presented for study 1 cohorts 11a to 11d as geometric mean MGX plasma concentrations for participants in the PK population (n = 6 per group) using linear (main figure) and semilogarithmic (inset) scales. IV, intravenous; n, number of participants; MGX, manogepix.CC BY · PubMed Central
FIG 5 MGX concentration profile using a loading dose strategy. Data are presented for study 1 cohort 12 as geometric mean MGX plasma concentrations for participants in the PK population (n = 6) using linear a scale. A 1000-mg FMGX dose was infused over 2 h at 0 and 9 h on day 1 followed by 600-mg FMGX doses infused over 1 h once daily for 6 days (days 2 to 7). FMGX, fosmanogepix; IV = intravenous; n, number of participants; MGX, manogepix; PK, pharmacokinetics.
FIG 5 MGX concentration profile using a loading dose strategy. Data are presented for study 1 cohort 12 as geometric mean MGX plasma concentrations for participants in the PK population (n = 6) using linear a scale. A 1000-mg FMGX dose was infused over 2 h at 0 and 9 h on day 1 followed by 600-mg FMGX doses infused over 1 h once daily for 6 days (days 2 to 7). FMGX, fosmanogepix; IV = intravenous; n, number of participants; MGX, manogepix; PK, pharmacokinetics.CC BY · PubMed Central
FIG 6 MGX concentration profile after single and multiple ascending oral FMGX doses. (A) SAD cohorts; (B) MAD cohorts. Data are presented for study 2 cohorts 1a and 1b (A) and cohorts 2 and 3 (B) as geometric mean MGX plasma concentrations for participants in the PK population (n = 8 for 400 mg p.o., n = 6 for all other treatment groups) using linear (panel A, main figure and panel B) and semilogarithmic (panel A, inset) scales. A single i.v. dose for bioequivalence was infused over 3 h; doses were administered daily for the MAD segment. The SAD and MAD phases were conducted under ante cibum and post cibum conditions, respectively. FMGX, fosmanogepix; n, number of participants; MAD, multiple ascending dose; MGX, manogepix; PO, oral, SAD, single ascending dose.
FIG 6 MGX concentration profile after single and multiple ascending oral FMGX doses. (A) SAD cohorts; (B) MAD cohorts. Data are presented for study 2 cohorts 1a and 1b (A) and cohorts 2 and 3 (B) as geometric mean MGX plasma concentrations for participants in the PK population (n = 8 for 400 mg p.o., n = 6 for all other treatment groups) using linear (panel A, main figure and panel B) and semilogarithmic (panel A, inset) scales. A single i.v. dose for bioequivalence was infused over 3 h; doses were administered daily for the MAD segment. The SAD and MAD phases were conducted under ante cibum and post cibum conditions, respectively. FMGX, fosmanogepix; n, number of participants; MAD, multiple ascending dose; MGX, manogepix; PO, oral, SAD, single ascending dose.CC BY · PubMed Central
FIG 7 Study design. IV, intravenous; MAD, multiple ascending dose; n, number of patients; PO, oral; QD, once daily; SAD, single ascending dose.
FIG 7 Study design. IV, intravenous; MAD, multiple ascending dose; n, number of patients; PO, oral; QD, once daily; SAD, single ascending dose.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Watanabe NA, Horii T, Miyazaki M, Hata K. 2011. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals, abstr F1-1378. Abstr Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM, Chicago, IL.
  2. Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, et al. 2017. APX001 protects immunosuppressed mice from Rhizopus delemar infection. Abstr IDweek 2017, San Diego, CA. Poster 1521.

Cited by

See all 52

Metadata

Authors
Hodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M.
Affiliations
  • Amplyx Pharmaceuticals (United States) (US)
  • Hearts Consulting Group, LLC, Poway, California, USA
  • Pfizer (United States) (US)
  • Kramer Consulting, LLC, North Potomac, Maryland, USA
  • ICON, Groningen, the Netherlands
Corresponding author
Hodges, Michael R.
Venue
Antimicrobial Agents and Chemotherapy
Published
2023-04-18
Volume
67
Issue
4
Pages
e0162322-e0162322
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W4361301291
Cited by
52
References
32
Citations by year
2026: 14 · 2025: 15 · 2024: 20 · 2023: 3
FWCI
10.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Amplyx
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
fosmanogepix, manogepix, pharmacokinetics, drug safety, invasive fungal infections, fungal cell wall biosynthesis, GPI-anchored proteins, healthy volunteers
MeSH terms
Invasive Fungal Infections, Adult, Aminopyridines, Antifungal Agents, Biological Availability, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Isoxazoles, Area Under Curve, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.